Clinical trials: Diabetic Nephropathy Type 2
Diabetic Nephropathy
To Determine the Effects of Avosentan on Doubling of Serum Creatinine, End Stage Renal Disease and Death in Diabetic Nephropathy
The purpose of this study is to determine whether avosentan (SPP301) is effective in decreasing morbidity and mortality in patients with diabetic nephropathy.
- Trial name
- NCT00120328
- Testing
- SPP301
- Where
- United States
- Volunteers
- 2,364 people
- Sponsor
- Speedel Pharma Ltd.
Diabetic Kidney Disease
Phase 2 Study of TMX-049 in Subjects With Type 2 Diabetes and Albuminuria
The primary objective of this study is to assess the effect of 2 dose levels of TMX-049 on urinary albumin excretion in subjects with Type 2 diabetes and albuminuria (a urinary albumin-to-creatinine ratio (UACR) 200 to 3000 mg/g…
- Trial name
- NCT03449199
- Testing
- TMX-049
- Where
- 55 sites in United States
- Volunteers
- 130 people
- Sponsor
- Teijin America, Inc.
Hypertension, Diabetic Nephropathies
A Prospective, Randomised, Double-blind, Double-dummy, Forced-titration, Multicentre, Parallel Group, One Year Treatment Trial to Compare Telmisartan (MICARDIS) 80 mg Versus Losartan (COZAAR) 100 mg, in Hypertensive Type 2 Diabetic Patients With Overt Nephropathy (AMADEO Study)
A number of blood pressure lowering drugs in the class known as angiotensin receptor blockers (ARB) have been shown to slow the decline in kidney function of patients with type 2 diabetes, high blood pressure, and kidney disease.
- Trial name
- NCT00168857
- Testing
- telmisartan, losartan
- Where
- 109 sites in United States, Argentina and 8 more
- Volunteers
- 860 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes Mellitus
A Study to Assess Efficacy and Safety of ASP1941 in Diabetic Patients With Renal Impairment
This study is to assess the effect of renal function on the efficacy and safety of ASP1941 in type 2 diabetic patients with mild to moderate renal impairment.
- Trial name
- NCT01316094
- Testing
- ASP1941
- Where
- 8 sites in Japan
- Volunteers
- 165 people
- Sponsor
- Astellas Pharma Inc
Diabetes, Magnetic Resonance Imaging
Cardiovascular Contrast-enhanced Magnetic Resonance Imaging Using Polysaccharide Superparamagnetic Iron Oxide Injection in Diabetic Patients
This is an open-label, single-center, single-dose study aims to evaluate the effect and safety of polymeric superparamagnetic iron oxide in cardiovascular magnetic resonance imaging for diabetic patients with concomitant chronic…
- Trial name
- NCT06051565
- Testing
- Polysaccharide superparamagnetic iron oxide injection
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Diabetic Nephropathy
Safety and Efficacy Study of Pyridorin in Patients With Nephropathy Due to Type 2 Diabetes
The primary objective of this study is to evaluate the efficacy of two different doses of Pyridorin (150 mg and 300 mg)compared to placebo in retarding the progression of diabetic nephropathy.
- Trial name
- NCT00734253
- Testing
- Pyridoxamine Dihydrochloride
- Where
- United States
- Volunteers
- 317 people
- Sponsor
- NephroGenex, Inc.
Chronic Kidney Disease, Type 2 Diabetes
The Phase II Study of Bardoxolone Methyl in Patients With Chronic Kidney Disease and Type 2 Diabetes; TSUBAKI Study
The purpose of this study is to assess the safety and efficacy of RTA 402 in chronic kidney disease (CKD) patients with type 2 diabetes in a double-blind, placebo-controlled study when this compound is administered once daily for…
- Trial name
- NCT02316821
- Testing
- RTA 402
- Where
- Japan
- Volunteers
- 216 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Renal Insufficiency, Chronic, Diabetes Mellitus, Type 2
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
This study assesses the efficacy of bardoxolone methyl relative to placebo in delaying progression to end-stage renal disease (ESRD) and cardiovascular deaths in patients with Stage 4 Chronic Kidney Disease (CKD) and type 2…
- Trial name
- BEACON (NCT01351675)
- Testing
- Bardoxolone Methyl: 20 mg
- Volunteers
- 2,185 people
- Sponsor
- Biogen
Diabetic Nephropathies
A Phase 2, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of PF-00489791 In Patients With Type 2 Diabetes And Overt Nephropathy
PF-00489791 is an inhibitor of phosphodiesterase type 5. Our hypothesis is that PF-00489791 will enhance the relaxation of blood vessels within the kidney and so reduce blood pressure, improving renal function.
- Trial name
- NCT01200394
- Testing
- PF-00489791
- Where
- 160 sites in United States, Australia and 13 more
- Volunteers
- 256 people
- Sponsor
- Pfizer
Diabetic Kidney Disease
P2a Open Label Study to Evaluate 2-HPβCD in Subjects With Diabetic Kidney Disease
This is an open label, two to three center study to evaluate the clinical efficacy and safety of 1 dose level of 2-hydroxypropyl-β-cyclodextrin (2-HPβCD) given intravenously in adult patients with type 2 diabetes with diabetic…
- Trial name
- NCT06489340
- Testing
- 2HPβCD
- Where
- United States
- Sponsor
- ZyVersa Therapeutics, Inc.
Hypertension, Diabetes
Tarka® vs. Lotrel® in Hypertensive, Diabetic Subjects With Renal Disease (TANDEM)
The primary objective of this study is to determine if trandolapril/verapamil (Tarka®) is superior to amlodipine/benazepril (Lotrel®) in reduction of albuminuria in hypertensive subjects with Type 2 diabetes mellitus (DM) and…
- Conditions
- Hypertension, Diabetes, Proteinuria
- Trial name
- TANDEM (NCT00234871)
- Testing
- trandolapril/verapamil, Lotrel (amlodipine/benazepril)
- Volunteers
- 357 people
- Sponsor
- Abbott
Diabetes Mellitus, Type 2, Liver Diseases
Validate Smart Breath Analyzer as Screening Tool for Diabetic, Hepatic, Renal, Lung, and Other Metabolic Disorders
This is a prospective, multicentric, non-treatment study to build and validate a portable, non-invasive smart breath analyzer that can screen underlying health issues using exhaled breath.
- Conditions
- Diabetes Mellitus, Type 2, Liver Diseases, Kidney Diseases, Lung Diseases
- Trial name
- RESPYR-SBA (NCT07646015)
- Where
- India
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Respyr
Diabetic Kidney Disease
Phase 2 Study of INV-202 in Patients With Diabetic Kidney Disease
The study is designed to assess the efficacy, safety, tolerability, and transformation within the human body of INV-202 investigational drug in the treatment of adult participants with a diagnosis of Diabetic Kidney Disease due…
- Trial name
- NCT05514548
- Testing
- INV-202
- Where
- 72 sites in United States, Canada and 5 more
- Volunteers
- 265 people
- Sponsor
- Inversago Pharma Inc.